GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Phathom Pharmaceuticals
The shares of Phathom Pharmaceuticals, a biotech company focused on gastrointestinal diseases, reflect expectations for its lead drug. The price chart is a story of how the FDA decisions, manufacturing issues, and the drug's potential to become a new standard of care are affected.
Share prices of companies in the market segment - Pharma git
Phathom Pharmaceuticals (PHAT) is a biopharmaceutical company focused on the development and commercialization of novel treatments for acid-related gastrointestinal diseases. We classify the company in the Pharmaceuticals/Gastroenterology segment. The chart below reflects the dynamics of this major therapeutic segment.
Broad Market Index - GURU.Markets
Phathom Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing drugs for the treatment of gastrointestinal disorders associated with acidity. It is a component of the GURU.Markets index, and the chart below shows how its stock compares to the broader market.
Change in the price of a company, segment, and market as a whole per day
PHAT - Daily change in the company's share price Phathom Pharmaceuticals
The volatility of Phathom Pharmaceuticals, a company specializing in gastrointestinal diseases, reflects the risks and opportunities of the pharmaceutical sector. Change_co measures the sensitivity to the commercial success of its first drug. This parameter is important for formulas on System.GURU.Markets that analyze companies with a single product.
Daily change in the price of a set of shares in a market segment - Pharma git
Phathom Pharmaceuticals, Inc. is a pharmaceutical company. This chart highlights the sector's high volatility. Comparing it to PHAT, which focuses on gastrointestinal diseases, helps understand its unique risk profile.
Daily change in the price of a broad market stock, index - GURU.Markets
Phathom is a biopharmaceutical company specializing in gastrointestinal treatments. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing Phathom's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Phathom Pharmaceuticals
Phathom is a biopharmaceutical company specializing in the treatment of gastrointestinal diseases. Its year-over-year performance reflects both the commercial success of its existing drugs and investor confidence in its R&D platform, which is focused on new breakthrough drugs.
Annual dynamics of market capitalization of the market segment - Pharma git
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the treatment of gastrointestinal diseases. Its success depends on the commercialization of its key drug. The chart shows how its focus on this vast market niche and the competitive environment influence its performance.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Phathom Pharmaceuticals is a biopharmaceutical company whose stock performance is driven by the commercialization of its products and progress in research. The company's business is not dependent on economic cycles. This chart reflects biotech events, not macroeconomic data.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Phathom Pharmaceuticals
The market capitalization of Phathom, a pharmaceutical company, depends on its product cycle. The monthly fluctuations on the chart reflect sales data for its drug for treating stomach acid disorders and its ability to compete in a large and established market.
Monthly dynamics of market capitalization of the market segment - Pharma git
Phathom Pharmaceuticals specializes in the development and commercialization of new treatments for gastrointestinal diseases, particularly those related to acidity. The chart below reflects overall investor sentiment in the pharmaceutical sector, where Phathom is targeting a large market with its new drug.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Phathom Pharmaceuticals focuses on treating gastrointestinal diseases. The company's success depends on the approval and sales of its drugs. Its stock price is event-driven, reacting sharply to FDA news and sales data, and is largely independent of overall market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Phathom Pharmaceuticals
Phathom Pharmaceuticals focuses on gastrointestinal drugs. Its weekly stock price is a classic example of biotech: sharp movements on news about trial results, FDA decisions, and the commercial prospects of its developments.
Weekly dynamics of market capitalization of the market segment - Pharma git
Phathom Pharmaceuticals is a biopharmaceutical company focused on gastroenterology. Comparing its weekly performance to a broad biotech index can reveal its unique characteristics. The chart will show how news about clinical trials of its drugs or FDA decisions give the stock a life of its own, separate from the general market noise.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Shares of Phathom Pharmaceuticals, a biotech company, live in a world of their own. Their performance is determined by news about clinical trials. A chart comparing the stock to the S&P 500 clearly demonstrates how the stock can rise or fall on company-specific events, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
PHAT - Market capitalization of the company Phathom Pharmaceuticals
Phathom Pharmaceuticals' market capitalization chart tells the story of an attempt to bring a new drug to market for stomach acid-related conditions. Its dynamics are a rollercoaster of development, reflecting FDA decisions, clinical trial data, and competition with existing drugs. It's a visualization of the risky path from development to commercialization.
PHAT - Share of the company's market capitalization Phathom Pharmaceuticals within the market segment - Pharma git
Phathom Pharmaceuticals is focused on developing and commercializing new treatments for acid-related gastrointestinal disorders. Its market share in the pharmaceutical sector reflects the potential of its products in the vast market for heartburn and ulcer medications. The chart below shows the weightings of its investors.
Market capitalization of the market segment - Pharma git
Phathom Pharmaceuticals specializes in the treatment of gastrointestinal disorders associated with acidity. The chart below shows the overall market capitalization of the pharmaceutical sector. It helps assess the scale of the market the company is targeting and the potential demand for its products if they are successfully launched.
Market capitalization of all companies included in a broad market index - GURU.Markets
This graph tells the story of the fight against heartburn at the molecular level. Phathom Pharmaceuticals is developing a new generation of drugs for acid-related gastrointestinal disorders. Its volatile line reflects the progress of clinical trials. It's a visualization of how a scientific breakthrough in one narrow field can create a multi-billion dollar market.
Book value capitalization of the company, segment and market as a whole
PHAT - Book value capitalization of the company Phathom Pharmaceuticals
Phathom Pharmaceuticals' capital consists of its financial reserves and rights to innovative drugs for the treatment of acid-related gastrointestinal diseases. Book value reflects the resources required to bring these drugs to market. The chart shows how clinical trial results and preparation for commercialization impacted the company's capital base.
PHAT - Share of the company's book capitalization Phathom Pharmaceuticals within the market segment - Pharma git
Phathom Pharmaceuticals brings new drugs to market for the treatment of gastrointestinal diseases. The company focuses on research and marketing, often outsourcing manufacturing. The chart shows a modest share of physical assets, as its business model does not include ownership of large pharmaceutical manufacturing plants.
Market segment balance sheet capitalization - Pharma git
Pharmaceuticals is a knowledge-intensive industry, but Phathom, when bringing new drugs to market, becomes moderately capital-intensive due to the need to invest in production and marketing. Given the assets of the entire sector, its model requires a balance between "light" R&D and "heavy" commercial operations.
Book value of all companies included in the broad market index - GURU.Markets
Phathom Pharmaceuticals' book value is not derived from its product lines, but primarily from its intellectual property and capital invested in clinical trials of new drugs for gastrointestinal diseases. These assets reflect the company's financial resources for conducting expensive research. The chart illustrates its scale in the biotech world.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Phathom Pharmaceuticals
Phathom Pharma doesn't have large manufacturing plants. Its market capitalization, which exceeds its book value, reflects investors' assessment of the potential of its drug for treating stomach acid disorders. The chart shows how market confidence in the product's success changed as clinical trials progressed.
Market to book capitalization ratio in a market segment - Pharma git
Phathom Pharmaceuticals is in the commercialization stage of its gastrointestinal drugs. Its valuation on this chart reflects investors' confidence in the market potential of its products. It's a classic pharma story: a high premium to book value for intellectual property and future sales.
Market to book capitalization ratio for the market as a whole
Phathom Pharmaceuticals specializes in developing drugs to treat gastrointestinal disorders associated with acidity. The company's valuation, currently in the commercialization stage, depends on the success of its product launches and their market potential. This chart helps understand the market premium for innovation in a large segment of the pharmaceutical market.
Debts of the company, segment and market as a whole
PHAT - Company debts Phathom Pharmaceuticals
Phathom Pharmaceuticals, focused on treating gastrointestinal diseases, uses debt to finance expensive clinical trials and the commercial launch of its drugs. This chart reflects the biotech company's financial strategy as it navigates the path from development to market, which requires significant upfront investment.
Market segment debts - Pharma git
Phathom Pharmaceuticals is a pharmaceutical company focused on developing drugs to treat gastrointestinal diseases. Like any development-stage biopharmaceutical company, it requires significant funding. This chart shows its capital structure and how it balances equity and debt financing to bring its products to market.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Phathom Pharmaceuticals
Phathom Pharmaceuticals focuses on treating gastrointestinal diseases. The journey from developing a molecule to bringing a drug to market takes years and hundreds of millions of dollars, often financed through debt. This chart shows the company's debt load, illustrating the financial risks it takes in the hopes of future commercial success for its drugs.
Market segment debt to market segment book capitalization - Pharma git
Phathom Pharmaceuticals specializes in developing drugs for the treatment of gastrointestinal diseases. Like many development-stage pharmaceutical companies, its financial health depends on the success of clinical trials. This chart shows how the company finances its operations, comparing its debt to the market capitalization of the entire pharmaceutical sector.
Debt to book value of all companies in the market
Phathom Pharmaceuticals focuses on treating gastrointestinal diseases. The path from drug development to market launch is long and expensive. Financing such projects often requires external capital. How heavily does the company rely on debt? This chart of total market debt helps assess its financial strength and the risks along the way.
P/E of the company, segment and market as a whole
P/E - Phathom Pharmaceuticals
Phathom Pharmaceuticals is a biopharmaceutical company specializing in the development of drugs for the treatment of gastrointestinal disorders associated with acidity. This chart shows how investors assess the commercial potential of its lead drug. The valuation is heavily dependent on sales success and drug competition.
P/E of the market segment - Pharma git
Phathom Pharmaceuticals specializes in the development and commercialization of new treatments for gastrointestinal diseases, particularly those related to acidity. This chart shows the average valuation for pharmaceutical companies specializing in the gastrointestinal tract, providing investors with context for assessing Phathom's scientific and commercial potential.
P/E of the market as a whole
Phathom Pharmaceuticals focuses on treating gastrointestinal diseases. The valuation of such companies often takes on a life of its own, depending on the success of clinical trials and regulatory approvals. Does comparing this chart reveal the extent to which Phathom investors are ignoring overall market trends, betting solely on the success of its drugs?
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Phathom Pharmaceuticals
Phathom Pharmaceuticals focuses on developing drugs to treat gastrointestinal disorders, particularly those associated with excess acidity. This chart illustrates projected profitability estimates based on the potential success of its key developments. Approval of a new drug could dramatically impact future cash flows.
%20P%2FE%20Phathom%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Phathom-Pharmaceuticals&v=1772603425576 "Chart of the company's future (projected) P/E Phathom Pharmaceuticals")
Future (projected) P/E of the market segment - Pharma git
Phathom Pharmaceuticals focuses on developing drugs to treat gastrointestinal disorders, particularly those related to excess acidity. This is a highly specialized area with high potential. The chart reflects average forecasts for the pharmaceutical sector, helping to understand whether the market favors Phathom as a promising company.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20git&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-git&v=1772603425582 "Future (projected) P/E graph of the market segment - Pharma git")
Future (projected) P/E of the market as a whole
Phathom Pharmaceuticals focuses on developing drugs for the treatment of gastrointestinal diseases. The company's commercial success depends on regulatory approval and market acceptance. This graph of overall investor sentiment influences the cost of capital and the market's willingness to finance the launch of new pharmaceuticals.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772603425588 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Phathom Pharmaceuticals
Phathom Pharmaceuticals focuses on treating gastrointestinal diseases. The company is in the early stages of drug introduction, so its financial performance reflects the balance between early revenues and significant R&D and marketing expenditures. This chart shows the company's journey from a biotech startup to a potentially profitable pharmaceutical company.
Profit of companies in the market segment - Pharma git
Phathom Pharmaceuticals focuses on treating gastrointestinal disorders caused by excess acidity. This chart shows the overall financial health of the pharmaceutical industry. Phathom's success depends on its ability to bring its drugs to market, and the overall profitability of the sector impacts the cost of clinical trials, partnerships, and investor sentiment.
Overall market profit
Phathom Pharmaceuticals challenges the status quo in gastrointestinal treatment by developing innovative drugs. The success of such biotechs directly impacts the overall profitability of the healthcare sector, changing its landscape. This chart shows how breakthrough technologies impact the financial health of the entire industry, where a single successful drug can spark a new wave of growth.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Phathom Pharmaceuticals
Phathom Pharmaceuticals is focused on developing drugs to treat gastrointestinal disorders associated with excess acidity. Its future depends on the approval and commercial success of new drugs. This chart shows analyst consensus forecasts for future sales, reflecting the market's confidence in the potential of its product portfolio.
%20profit%20of%20the%20company%20Phathom%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Phathom-Pharmaceuticals&v=1772603425670 "Graph of future (projected) profit of the company Phathom Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Pharma git
Phathom Pharmaceuticals develops and commercializes drugs for the treatment of gastrointestinal diseases. The company's success depends on regulatory approval and market acceptance of its products. This chart shows general profitability expectations for the pharmaceutical segment, providing context for assessing the potential commercial success of new drugs in this niche.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20git&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-git&v=1772603425698 "Graph of future (predicted) profits of companies in a market segment - Pharma git")
Future (predicted) profit of the market as a whole
Phathom Pharmaceuticals focuses on gastrointestinal medications. Health isn't dependent on the economy, but the company's financial health is. This graph of corporate earnings expectations reflects the investment climate. During periods of growth, companies find it easier to raise funds for research and development, which is necessary to bring new drugs to market.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772603425718 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Phathom Pharmaceuticals
Phathom Pharmaceuticals is focused on developing and commercializing new treatments for gastrointestinal diseases. This chart is especially important for the company at the product launch stage. It shows how investors evaluate the potential sales volume of its drugs, assigning a premium to each dollar of expected revenue in a promising pharmaceutical segment.
P/S market segment - Pharma git
Phathom Pharmaceuticals is focused on developing drugs to treat gastrointestinal diseases, a huge market with unmet needs. The company's value depends on the success of its clinical trials and future commercial potential. This chart shows how investors typically value pharmaceutical industry revenue, providing context for Phathom's valuation.
P/S of the market as a whole
Phathom Pharmaceuticals focuses on developing drugs to treat gastrointestinal disorders associated with hyperacidity. The company's business operates at the intersection of science and commerce. This chart provides an overview of the overall market revenue estimate. For Phathom, it serves as a measure of how well its future sales expectations meet or exceed market averages.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Phathom Pharmaceuticals
Phathom Pharmaceuticals is focused on developing drugs to treat gastrointestinal conditions such as heartburn. The company is at a stage where the future commercial success of its developments is more important than current performance. This metric reflects market sales expectations following the potential approval and launch of its key drug in a large market.
%20P%2FS%20Phathom%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Phathom-Pharmaceuticals&v=1772603425836 "The graph of the company's future (projected) P/S Phathom Pharmaceuticals")
Future (projected) P/S of the market segment - Pharma git
Phathom Pharmaceuticals specializes in the development and commercialization of new treatments for acid-related gastrointestinal diseases. The company's success depends on the approval and adoption of its drugs. This chart reflects the average revenue estimate for its pharmaceutical segment, allowing investors to understand how Phathom's expectations compare to those of other companies.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20git&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-git&v=1772603425896 "Future (projected) P/S market segment graph - Pharma git")
Future (projected) P/S of the market as a whole
Phathom Pharmaceuticals focuses on treating gastrointestinal disorders caused by excess acidity. This chart illustrates investor expectations for future revenue overall. The commercial success of Phathom's products depends on its ability to offer more effective solutions to millions of people, making the company a significant player in the vast gastroenterology market.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772603425954 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Phathom Pharmaceuticals
This chart shows the revenue of Phathom Pharmaceuticals, a company focused on developing and commercializing drugs for the treatment of gastrointestinal diseases. Its sales are directly dependent on the successful launch of new drugs and their acceptance by the medical community. The dynamics demonstrate the demand for its therapeutic solutions among patients and doctors.
Sales of companies in the market segment - Pharma git
Phathom Pharmaceuticals is focused on developing and commercializing new treatments for gastrointestinal diseases associated with hyperacidity. The dynamics shown in this graph illustrate the size of the gastroenterology market. Phathom's innovative drugs have the potential to change treatment standards and capture a significant share, influencing the overall revenue structure of the segment.
Overall market sales
Phathom Pharmaceuticals develops drugs for the treatment of gastrointestinal diseases. Although demand for drugs is less elastic, the overall economic situation reflected in this chart impacts healthcare systems and their budgets, which can affect the speed of new drug introductions and their pricing.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Phathom Pharmaceuticals
Phathom Pharmaceuticals focuses on treating gastrointestinal diseases. The company's future revenue depends on the successful launch of new drugs and their acceptance by the medical community. This chart visualizes analysts' forecasts for the commercial potential of Phathom's developments.
%20sales%20of%20the%20company%20Phathom%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Phathom-Pharmaceuticals&v=1772603426157 "Schedule of future (projected) sales of the company Phathom Pharmaceuticals")
Future (projected) sales of companies in the market segment - Pharma git
Phathom Pharmaceuticals is focused on developing and commercializing new treatments for gastrointestinal diseases, particularly those related to acidity. The company's success depends on regulatory approval and its ability to compete with existing therapies. This pharmaceutical market forecast in this area demonstrates the overall potential demand for such innovations.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20git&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-git&v=1772603426164 "Schedule of future (projected) sales of companies in the market segment - Pharma git")
Future (projected) sales of the market as a whole
Phathom Pharmaceuticals focuses on medications for gastrointestinal diseases. The company's commercial success depends on overall consumer spending on healthcare. The graph below provides an overview of overall purchasing power, while Phathom's sales demonstrate how much the population is willing to spend on modern, more expensive medications to improve quality of life.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772603426182 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Phathom Pharmaceuticals
Phathom Pharmaceuticals is focused on developing drugs for the treatment of gastrointestinal diseases. The company is at the market launch stage, so its financial performance reflects significant R&D and marketing expenditures. The chart illustrates these investments, which form the foundation for future commercial profitability.
Market segment marginality - Pharma git
Phathom Pharmaceuticals specializes in the development and commercialization of new treatments for gastrointestinal diseases associated with hyperacidity. Profitability depends on the market success of their products and regulatory approval. This chart shows operational results as they progress toward market launch. A comparison with the industry benchmark highlights their commercial potential.
Market marginality as a whole
Phathom Pharmaceuticals focuses on treating gastrointestinal disorders associated with hyperacidity. Their innovative drugs are designed to change the standard in this field. This chart reflects the overall state of competition in the market. Phathom's success depends on their ability to offer a more effective solution, allowing them to occupy a highly profitable niche.
Employees in the company, segment and market as a whole
Number of employees in the company Phathom Pharmaceuticals
Phathom Pharmaceuticals specializes in gastrointestinal treatments. As it moves from clinical trials to commercialization, its team is undergoing transformation. This chart shows growth, particularly in the sales and marketing departments, indicating preparation for the new product's launch.
Share of the company's employees Phathom Pharmaceuticals within the market segment - Pharma git
Phathom Pharmaceuticals focuses on developing drugs for the treatment of gastrointestinal diseases. The data presented reflects the company's human capital footprint in its highly specialized pharmaceutical niche. The dynamics of this indicator reflect the scale of its clinical trials, as each phase of testing involves a growing team of scientists, physicians, and researchers.
Number of employees in the market segment - Pharma git
Phathom Pharmaceuticals is focused on the development and commercialization of new treatments for gastrointestinal diseases. This chart shows employment trends in the highly specialized niche of gastroenterological pharmacology. The growth of scientific and commercial staff in this field is directly related to progress in clinical trials and the growing demand for innovative drugs.
Number of employees in the market as a whole
Phathom Pharmaceuticals specializes in developing drugs for the treatment of gastrointestinal diseases. The company's success depends on clinical trial results and regulatory approvals. This metric reflects how developments in the pharmaceutical sector, where Phathom operates, impact overall employment, particularly in science, medicine, and clinical research.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Phathom Pharmaceuticals (PHAT)
Phathom Pharmaceuticals is focused on developing treatments for gastrointestinal diseases. Like many biotech companies, its value is not determined by current sales. This chart shows a high valuation of intellectual capital: the market sees value in its patent portfolio and clinical development. This is a bet on the future success of its drugs, developed by a small team of scientists.
%20of%20the%20company%20Phathom%20Pharmaceuticals%20(PHAT)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Phathom-Pharmaceuticals-PHAT&v=1772603426338 "Chart of market capitalization per employee (in thousands of dollars) of the company Phathom Pharmaceuticals (PHAT)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma git
Phathom Pharmaceuticals specializes in drugs for gastrointestinal diseases. The company's value is determined by its development pipeline and future sales potential. This chart illustrates how investors evaluate the prospects of its R&D pipeline, where a small team of scientists can create a product worth billions of dollars.
%20by%20market%20segment%20-%20Pharma%20git&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-git&v=1772603426360 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma git")
Market capitalization per employee (in thousands of dollars) for the overall market
Phathom Pharmaceuticals specializes in developing drugs to treat gastrointestinal disorders associated with acidity. The chart shows the valuation of a company bringing a new class of drugs to market. The high cost per employee reflects the huge potential market for its products and the value of its intellectual property.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772603426377 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Phathom Pharmaceuticals (PHAT)
Phathom Pharmaceuticals develops and commercializes drugs for the treatment of gastrointestinal diseases. The company operates at the intersection of R&D and commercialization, bringing new drugs to market. This chart shows how the company balances costs. Efficiency here refers to the ability of a small team of specialists to manage expensive clinical trials and build future sales.
%20Chart%20Phathom%20Pharmaceuticals%20(PHAT)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Phathom-Pharmaceuticals-PHAT&v=1772603426417 "Company Profit Per Employee (in thousands of dollars) Chart Phathom Pharmaceuticals (PHAT)")
Profit per employee (in thousands of dollars) in the market segment - Pharma git
Phathom Pharmaceuticals is a biopharmaceutical company focused on treating gastrointestinal diseases (such as GERD). The company is in the commercialization phase of its first drug. This metric reflects a critical transition from R&D costs (losses per employee) to generating initial sales revenue through its new marketing and sales team.
%20in%20the%20market%20segment%20-%20Pharma%20git&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-git&v=1772603426426 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma git")
Profit per employee (in thousands of dollars) for the market as a whole
Phathom Pharmaceuticals is a biopharmaceutical company focused on treating gastrointestinal diseases (such as GERD). They have approved drugs. This chart should show the transition from R&D losses to profitability. It reflects how successfully the company's commercial team is bringing new drugs to a highly competitive market, per employee.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772603426478 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Phathom Pharmaceuticals (PHAT)
Phathom Pharmaceuticals specializes in gastrointestinal medications. This chart shows the company's return on intellectual property. Growth in this figure, especially after approval of a new drug, reflects successful market launches and the effectiveness of its small sales and marketing team.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Phathom-Pharmaceuticals-PHAT&v=1772603426491 "Sales chart per company employee Phathom Pharmaceuticals (PHAT)")
Sales per employee in the market segment - Pharma git
Phathom Pharmaceuticals focuses on gastrointestinal therapeutics. This chart measures how effectively their team—from lab scientists to sales specialists—brings products to market. It compares Phathom's revenue per employee to the average for the specialty pharmaceutical segment, demonstrating their commercial profitability.
Sales per employee for the market as a whole
Phathom Pharmaceuticals (PHAT) specializes in the treatment of gastrointestinal diseases and is bringing its flagship drug to market. The company is in the active commercialization phase. This metric is critical for assessing the transition from R&D to sales: it demonstrates how effectively sales representatives and marketers convert launch costs into actual revenue.
Short shares by company, segment and market as a whole
Shares shorted by company Phathom Pharmaceuticals (PHAT)
Phathom Pharmaceuticals focuses on drugs for gastrointestinal disorders, particularly those related to acidity. The bearish sentiment reflected in this chart may be related to concerns about regulatory approval (FDA) or their ability to compete with established treatments in the vast market.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Phathom-Pharmaceuticals-PHAT&v=1772603426655 "Short Shares Chart for the Company Phathom Pharmaceuticals (PHAT)")
Shares shorted by market segment - Pharma git
Phathom Pharmaceuticals is a company focused on treating gastrointestinal diseases. Their key product is Voquezna, a treatment for erosive esophagitis. This chart shows skepticism. "Shorts" here are betting that their drug will fail to gain market share from older generics or that new challenges will arise with FDA approval.
Shares shorted by the overall market
Phathom Pharmaceuticals (PHAT) is a biotech company focused on treating gastrointestinal diseases, specifically a new class of heartburn medications (a competitor to older PPIs). This chart highlights concerns about their commercial success. Bears may believe the market is already saturated with cheap generics, and doctors will not switch to a new, expensive drug without clear advantages.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Phathom Pharmaceuticals (PHAT)
Phathom Pharmaceuticals focuses on drugs for the treatment of acid-related gastrointestinal disorders. Success depends on approval and sales. This chart can soar above 70 on positive FDA news or strong sales. A range below 30 is often associated with trial failures, delays, or competitive concerns.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Phathom-Pharmaceuticals-PHAT&v=1772603426727 "RSI 14 indicator chart for the company's stock Phathom Pharmaceuticals (PHAT)")
RSI 14 Market Segment - Pharma git
Phathom (PHAT) is a biotech company focused on treating gastrointestinal (acid-related) diseases like GERD. The RSI_14_Seg for "Pharma git" (biotech) shows the overall sentiment. The chart helps us understand: is PHAT's volatility a reaction to its clinical trials, or is the entire biotech sector overheated (or oversold)?
RSI 14 for the overall market
Phathom (PHAT) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast PHAT (Phathom Pharmaceuticals)
Phathom (PHAT) is a pharmaceutical company focused on treating gastrointestinal diseases, particularly acid reflux. This chart shows the average 12-month forecast of analysts. It reflects their collective assessment of the new drug's commercial launch and its ability to capture market share in a mature market.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-PHAT-Phathom-Pharmaceuticals&v=1772603426789 "A chart showing analyst consensus forecasts for the expected stock price. PHAT (Phathom Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price PHAT (Phathom Pharmaceuticals)
Phathom Pharmaceuticals is a biopharmaceutical company specializing in the treatment of gastrointestinal diseases, specifically drugs for GERD (heartburn) and H. pylori. This chart measures the gap between the current price and the consensus target price. It shows the commercial potential analysts see for their drug.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-PHAT-Phathom-Pharmaceuticals&v=1772603426790 "A chart showing the difference between the consensus forecast and the actual stock price. PHAT (Phathom Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Pharma git
Phathom Pharmaceuticals is a company challenging the heartburn pill market. Its flagship drug, Voquezna, is a new class of medication (P-CAB) for the treatment of GERD and H. pylori. This chart shows analysts' overall expectations across the pharmaceutical sector. It reflects whether experts believe the new drug can displace established blockbusters.
Analysts' consensus forecast for the overall market share price
Phathom Pharmaceuticals is a biopharmaceutical company focused on the treatment of gastrointestinal diseases, particularly erosive esophagitis. This chart shows overall market sentiment. For Phathom, which is launching a new drug (a competitor to older blockers), how these expectations (healthcare budgets) impact its commercialization is important. (349)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Phathom Pharmaceuticals
Phathom (PHAT) is a biopharmaceutical company focused on acid gastrointestinal disease (GERD). Their signature product is Voquenza, a new, potentially more potent acid blocker than older PPIs (omeprazole). This chart is a gauge of the commercial battle. It measures their ability to convince doctors and patients to switch to their new (and more expensive) drug.
AKIMA Market Segment Index - Pharma git
Phathom (PHAT) is a biotech (partner of Takeda) focused on gastroenterology (GI); the company launched Voquezna, the first new class of drugs for the treatment of heartburn (GERD) and H. pylori in 30 years. This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does this breakthrough (new class) model (PHAT) differentiate it from the average pharma company?
The AKIM Index for the overall market
Phathom Pharmaceuticals is a commercial biopharmaceutical company focused on the treatment of acid-related gastrointestinal diseases. Its key product is Voquezna. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this new drug launch compares to overall economic trends.
